VC: Gemin X leads with $65M second round



Gemin X leads with $65M second round.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Gemin X
Montreal

$65.2M
second round

H.I.G., Sanderling

Funding will support Gemin X's continued clinical development of lead product candidate GX15-070, including an ongoing Phase I/II trial in patients with chronic lymphocytic leukemia and a Phase I trial in patients with solid tumors.

Oxagen
Abingdon, UK

$59.8M
second round

MPM Capital

The funds will advance Oxagen's small molecule anti-inflammatory for asthma to the clinic and expand the company's clinical and pre-clinical stage portfolio.

Phenomix
San Diego

$40M
second round

JPMorgan Partners, Delphi Ventures

The money will allow Phenomix to steer its lead drug into human trials.

Cylene Pharmaceuticals
San Diego

$26.3M
second round

Coastview Capital

The funding will allow Cylene to advance CX-3543, its lead product for the treatment of multiple cancers, into clinical development.

Aperon Biosystems
Palo Alto, CA

$15.3M
second round

Canaan Partners

Aperon is developing an in-home monitor for daily measurement of exhaled nitric oxide for the management of asthma.

Innovative Biosensors
College Park, MD

$3.5M
first round

Harbert Venture Partners

Innovative Biosensors is developing technologies for the rapid detection of pathogens.

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.